Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

Intrinsic cross-resistance to inhibition of different signaling pathways may hamper development of combinatorial treatments in melanoma, but the relative frequency of this phenotype and the strategies to overcome this hurdle remain poorly understood. Among 49 BRAF-mutant melanoma cell lines from pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Penna, Ilaria, Molla, Alessandra, Grazia, Giulia, Cleris, Loredana, Nicolini, Gabriella, Perrone, Federica, Picciani, Benedetta, Del Vecchio, Michele, de Braud, Filippo, Mortarini, Roberta, Anichini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826182/
https://www.ncbi.nlm.nih.gov/pubmed/26678033
http://dx.doi.org/10.18632/oncotarget.6600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826182/
https://www.ncbi.nlm.nih.gov/pubmed/26678033
http://dx.doi.org/10.18632/oncotarget.6600

Ejemplares similares